Atlantic Union Bankshares Corp cut its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 2.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 130,765 shares of the company’s stock after selling 2,663 shares during the period. Atlantic Union Bankshares Corp’s holdings in AbbVie were worth $29,878,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in the stock. Eclectic Associates Inc. ADV boosted its holdings in AbbVie by 0.8% in the fourth quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock valued at $1,337,000 after acquiring an additional 45 shares during the last quarter. Weil Company Inc. boosted its holdings in AbbVie by 2.3% in the third quarter. Weil Company Inc. now owns 2,026 shares of the company’s stock valued at $469,000 after acquiring an additional 46 shares during the last quarter. Hardin Capital Partners LLC boosted its holdings in AbbVie by 1.4% in the fourth quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company’s stock valued at $759,000 after acquiring an additional 46 shares during the last quarter. Dogwood Wealth Management LLC boosted its holdings in AbbVie by 10.8% in the fourth quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock valued at $108,000 after acquiring an additional 46 shares during the last quarter. Finally, Inlet Private Wealth LLC boosted its holdings in AbbVie by 0.3% in the third quarter. Inlet Private Wealth LLC now owns 17,001 shares of the company’s stock valued at $3,937,000 after acquiring an additional 47 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.
Insider Buying and Selling at AbbVie
In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. 0.06% of the stock is currently owned by corporate insiders.
Key Stories Impacting AbbVie
- Positive Sentiment: Evercore ISI recently raised its price target on AbbVie to $236 from $232 and kept an Outperform rating, reinforcing the bullish analyst tone around the shares. Why AbbVie Inc. (ABBV) is One of the Best Healthcare Stocks to Buy for the Long Term
- Positive Sentiment: AbbVie’s full-year 2026 adjusted EPS guidance of $14.37 to $14.57 appears to be supporting confidence that earnings can remain durable even as the company transitions beyond Humira. AbbVie rises 3.3% as upbeat 2026 outlook and fresh analyst optimism lift sentiment
- Positive Sentiment: Recent articles highlighting strong long-term growth potential, rising dividends, and improving drug portfolio sentiment are helping position ABBV as a defensive healthcare name with income appeal. 3 Reasons to Buy AbbVie Stock (ABBV) Like There’s No Tomorrow
- Neutral Sentiment: At the 2026 Annual Meeting, shareholders elected directors and maintained AbbVie’s governance structure; this is supportive of continuity, but not likely a major stock-moving catalyst on its own. AbbVie Shareholders Back Directors, Maintain Governance Structure
- Neutral Sentiment: Several recent writeups argue that AbbVie’s growth engine is “firing on all cylinders,” largely due to SKYRIZI and RINVOQ, but these are more confirmation of the current narrative than a fresh catalyst. AbbVie’s Growth Engine Is Firing On All Cylinders
- Negative Sentiment: Some commentary remains cautious, noting that AbbVie has lagged the broader market over the past year and still faces pressure from competition and investor skepticism around its longer-term multiple. AbbVie Stock: Is Wall Street Bullish or Bearish?
- Negative Sentiment: News that a smaller biotech beat one of AbbVie’s major drug programs is a reminder that competitive risks remain in key therapeutic areas. A Tiny Biotech Just Beat AbbVie’s $17 Billion Drug. Should Investors Be Worried?
AbbVie Stock Performance
Shares of ABBV stock opened at $207.83 on Wednesday. The company has a market capitalization of $367.20 billion, a price-to-earnings ratio of 102.38, a PEG ratio of 0.70 and a beta of 0.32. AbbVie Inc. has a 52-week low of $176.57 and a 52-week high of $244.81. The company has a 50-day simple moving average of $211.75 and a two-hundred day simple moving average of $220.44.
AbbVie (NYSE:ABBV – Get Free Report) last announced its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter in the previous year, the business earned $2.46 EPS. The company’s revenue was up 12.4% compared to the same quarter last year. On average, sell-side analysts forecast that AbbVie Inc. will post 14.32 EPS for the current fiscal year.
AbbVie Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. AbbVie’s dividend payout ratio is presently 340.89%.
Wall Street Analyst Weigh In
Several analysts recently commented on ABBV shares. UBS Group reduced their target price on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. Guggenheim restated a “buy” rating and set a $249.00 price target on shares of AbbVie in a report on Friday, May 1st. Royal Bank Of Canada assumed coverage on AbbVie in a report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price target on the stock. DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Finally, BMO Capital Markets restated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $252.90.
View Our Latest Stock Report on AbbVie
About AbbVie
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Read More
- Five stocks we like better than AbbVie
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
